1. Home
  2. KALU vs TRVI Comparison

KALU vs TRVI Comparison

Compare KALU & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaiser Aluminum Corporation

KALU

Kaiser Aluminum Corporation

BUY

Current Price

$149.33

Market Cap

3.0B

Sector

Industrials

ML Signal

BUY

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$12.92

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALU
TRVI
Founded
1946
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
KALU
TRVI
Price
$149.33
$12.92
Analyst Decision
Buy
Strong Buy
Analyst Count
4
10
Target Price
★ $168.25
$28.18
AVG Volume (30 Days)
159.5K
★ 1.8M
Earning Date
10-21-2026
11-12-2026
Dividend Yield
★ 2.02%
N/A
EPS Growth
★ 135.89
31.91
EPS
★ 9.43
N/A
Revenue
★ $1,585,900,000.00
N/A
Revenue This Year
$42.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.15
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$76.46
$9.29
52 Week High
$199.89
$20.22

Technical Indicators

Market Signals
Indicator
KALU
TRVI
Relative Strength Index (RSI) 43.39 20.25
Support Level $148.79 $10.13
Resistance Level $150.00 $13.55
Average True Range (ATR) 5.44 0.60
MACD 0.40 -0.11
Stochastic Oscillator 49.45 18.82

Price Performance

Historical Comparison
KALU
TRVI

About KALU Kaiser Aluminum Corporation

Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: